Contact Us

Defective Drugs
*    Denotes required field.

   * First Name 

   * Last Name 

   * Email 

Phone 

Cell Phone 

Street Address 

Zip Code 

City 

State 

   * Name of drug: 

Date you started taking this drug:

Date you stopped taking this drug:

Please describe side effects:

For verification purposes, please answer the below question:
+
=

No Yes, I agree to the Parker Waichman LLP disclaimers. Click here to review.

Yes, I would like to receive the Parker Waichman LLP monthly newsletter, InjuryAlert.

please do not fill out the field below.


Botox, Similar Products To Bear Black Box Warnings

Apr 30, 2009 | Parker Waichman LLP

Botox, Botox Cosmetic  and other botulinum toxin injections will bear new black box warnings regarding the risk of adverse events when toxin spreads beyond the site where it was injected.  A black box warning is the Food & Drug Administration's (FDA) most serious safety warning.

Botox, which is made with botulinum toxin type A, is approved for treatment of conditions such as blepharospasm (spasm of the eyelids), cervical dystonia (severe neck muscle spasms), and severe primary axillary hyperhydrosis (excess sweating).  Botox Cosmetic, which also uses botulinum toxin Type A, is approved for temporary improvement in the appearance of moderate to severe facial frown lines. A third product, Myobloc,  is made from botulinum toxin Type B and is approved for the treatment of adults with cervical dystonia.
The new black box warning will also apply to Dysport, a botulinum toxin product that was just approved for use in the U.S. by the FDA today.

The consumer advocacy group, Public Citizen had petitioned the FDA to issue warnings to doctors about  hospitalizations and deaths associated with the use of botulinum toxin products. The group had pressed for a black box warning.

Last February, the FDA launched a safety review of botulinum toxin injections, including Botox and Botox Cosmetic. transmission harmful unfavourable  The most serious cases had outcomes that included hospitalization and death, and occurred mostly in children treated for cerebral palsy-associated limb spasticity. Use of botulinum toxins for treatment of limb spasticity (severe arm and leg muscle spasms) in children or adults is not an approved use in the U.S. The FDA said that the adverse reactions may have been due to overdosing.

In addition to the new black box warning, the FDA said today that it will require that manufacturers develop and implement a Risk Evaluation and Mitigation Strategy [REMS], including a communication plan to provide more information regarding the risk for distant spread of botulinum toxin effects after local injection, as well as information to explain that botulinum toxin products cannot be interchanged. The REMS would also include a Medication Guide that explains the risks to patients, their families, and caregivers.

The FDA also said today that it is requiring the manufacturers to submit safety data after multiple administrations of the product in a specified number of children and adults with spasticity to assess the signal of serious risk regarding distant spread of toxin effects.


Other articles
Parker Waichman Accolades And Reviews Best Lawyers Find Us On Avvo